English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background and Purpose— We investigated whether clot permeability can predict clinically relevant outcomes in patients with atrial fibrillation (AF) treated with rivaroxaban. Methods— In the cohort study, we enrolled 232 consecutive patients with AF on rivaroxaban 20 mg/d (76.3%) or 15 mg/d (23.7%) for at least 3 months. Plasma clot permeability (Ks ), a measure of fibrin network density, was determined 24 to 30 hours since the intake of rivaroxaban at undetectable drug’s levels. Ischemic cerebrovascular events and bleedings were recorded.Results— During a median follow-up of 48 months, patients with Ks below median (6.8 cm2 ·10−9 ) had higher prevalence of stroke (5.84 versus 0.88% per year;P &lt;0.0001) and relevant bleeding (7.06 versus 0.88% per year;P &lt;0.0001) compared with those above median. The mortality rate was 1.53% per year and was not associated with Ks . Lower Ks predicted cerebrovascular ischemic events (hazard ratio, 6.64; 95% CI, 2.2–20.1) and relevant bleedings (hazard ratio, 7.38; 95% CI, 2.58–21.10). Minor bleeds (32.8% of patients) were observed more often in patients with Ks above median (50.9 versus 14.7%;P &lt;0.0001). Multivariate Cox regression analysis showed that in AF patients on rivaroxaban lower Ks increased the risk of stroke (hazard ratio, 6.51; 95% CI, 2.14–19.75) and relevant bleedings (hazard ratio, 9.68; 95% CI, 3.21–29.18).Conclusions— Decreased clot permeability in AF patients can predict thromboembolic and clinically relevant bleeding events during therapy with rivaroxaban, while looser clot networks predispose to minor bleeds.

Altered Fibrin Clot Properties Predict Stroke and Bleedings in Patients With Atrial Fibrillation on Rivaroxaban